Recombinant human growth hormone - Changchun Institute of Biological Products

Drug Profile

Recombinant human growth hormone - Changchun Institute of Biological Products

Latest Information Update: 08 Sep 2016

Price : $50

At a glance

  • Originator Changchun Institute of Biological Products
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Somatotropin deficiency

Most Recent Events

  • 30 Aug 2016 Preclinical trials in Somatotropin deficiency in China (Injection) before August 2016 (Changchun Institute of Biological Products pipeline, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top